Molecular Pathogenesis Unit, Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy.
Curr Med Chem. 2010;17(17):1730-55. doi: 10.2174/092986710791111215.
The recombinant antibodies in single-chain format (scFv) have found broad applications in both therapeutic and diagnostic fields. Tumour-associated antigens (TAAs) are proteins or other molecular species expressed in a specific tumour type, that can be targeted for diagnostic and immunotherapy purposes. The possibility of obtaining highly selective and efficacious scFvs makes them appropriate tools to target TAAs. The approach utilised for targeting depends on the nature of TAAs and their cell localisation. Tumour antigens displayed on the cell surface can be recognised by scFvs coupled to radioisotopes, toxins and enzymes to be used in cancer diagnosis and therapy. Intracellular tumour antigens can be targeted by scFvs expressed as "intracellular antibodies". This review reports the existing scFv-based formats, hints of their generation and pharmacokinetics, and a description of the most promising TAAs. It also provides an update of in vitro, preclinical and clinical studies using scFvs against TAAs for cancer diagnosis and treatment, with their merits and limits.
单链抗体(scFv)形式的重组抗体在治疗和诊断领域都有广泛的应用。肿瘤相关抗原(TAA)是在特定肿瘤类型中表达的蛋白质或其他分子种类,可以作为诊断和免疫治疗的靶标。获得高选择性和高效 scFv 的可能性使它们成为靶向 TAA 的合适工具。所使用的靶向方法取决于 TAA 的性质及其细胞定位。可以通过与放射性同位素、毒素和酶偶联的 scFv 来识别细胞表面上显示的肿瘤抗原,用于癌症诊断和治疗。可以通过表达为“细胞内抗体”的 scFv 来靶向细胞内肿瘤抗原。这篇综述报告了现有的基于 scFv 的格式、它们的产生和药代动力学的提示,以及最有前途的 TAA 的描述。它还提供了使用针对 TAA 的 scFv 进行癌症诊断和治疗的体外、临床前和临床研究的最新情况,包括它们的优点和局限性。